Anti-TMPRSS2 is a monoclonal antibody with possible antiviral activity that detects transmembrane serine protease 2 (TMPRSS2). MW: 146.06 KD.

Anti-TMPRSS2 is a monoclonal antibody with possible antiviral activity that detects transmembrane serine protease 2 (TMPRSS2). MW: 146.06 KD.

Anti-TMPRSS2 is a monoclonal antibody with possible antiviral activity that detects transmembrane serine protease 2 (TMPRSS2). MW: 146.06 KD.

Anti-TNFRSF21 / DR6 / CD358 is a humanized monoclonal antibody that specifically targets TNFRSF21. It can be used in treatment of cancer. MW :150 KD.

Anti-TNFRSF21 / DR6 / CD358 is a humanized monoclonal antibody that specifically targets TNFRSF21. It can be used in treatment of cancer. MW :150 KD.

Anti-TNFRSF21 / DR6 / CD358 is a humanized monoclonal antibody that specifically targets TNFRSF21. It can be used in treatment of cancer. MW :150 KD.

Anti-TNFRSF4 / OX40 / CD134 (BMS-986178) is a fully human immunoglobulin monoclonal antibody targeting OX40. It is used in treatment of in patients with advanced solid tumors. MW :150 KD.

Anti-TNFRSF4 / OX40 / CD134 (BMS-986178) is a fully human immunoglobulin monoclonal antibody targeting OX40. It is used in treatment of in patients with advanced solid tumors. MW :150 KD.

Anti-TNFRSF4 / OX40 / CD134 (BMS-986178) is a fully human immunoglobulin monoclonal antibody targeting OX40. It is used in treatment of in patients with advanced solid tumors. MW :150 KD.

Anti-TNFRSF5 / CD40 (Emory U. anti-CD40) is a monoclonal antibody against CD40 (also called TNFRSF5) with potential antitumor activity. MW: 143.74 KD.

Anti-TNFRSF5 / CD40 (Emory U. anti-CD40) is a monoclonal antibody against CD40 (also called TNFRSF5) with potential antitumor activity. MW: 143.74 KD.

Anti-TNFRSF5 / CD40 (Emory U. anti-CD40) is a monoclonal antibody against CD40 (also called TNFRSF5) with potential antitumor activity. MW: 143.74 KD.

Anti-TNFSF12 / TWEAK is a humanized monoclonal antibody directed against the apoptotic ligand TNF-like weak inducer of apoptosis (TWEAK) with potential antineoplastic activity. It is used to treat renal interstitial fibrosis. MW : 145.5 KD.

Anti-TNFSF12 / TWEAK is a humanized monoclonal antibody directed against the apoptotic ligand TNF-like weak inducer of apoptosis (TWEAK) with potential antineoplastic activity. It is used to treat renal interstitial fibrosis. MW : 145.5 KD.

Anti-TNFSF12 / TWEAK is a humanized monoclonal antibody directed against the apoptotic ligand TNF-like weak inducer of apoptosis (TWEAK) with potential antineoplastic activity. It is used to treat renal interstitial fibrosis. MW : 145.5 KD.

Anti-TNFSF13 / APRIL / CD256 (BION-1301) is a humanized antibody targeting a proliferation Inducing Ligand (APRIL, TNFSF13). It can be used in the treatment of IgA nephropathy. MW :150 KD.

Anti-TNFSF13 / APRIL / CD256 (BION-1301) is a humanized antibody targeting a proliferation Inducing Ligand (APRIL, TNFSF13). It can be used in the treatment of IgA nephropathy. MW :150 KD.

Anti-TNFSF13 / APRIL / CD256 (BION-1301) is a humanized antibody targeting a proliferation Inducing Ligand (APRIL, TNFSF13). It can be used in the treatment of IgA nephropathy. MW :150 KD.

Anti-TNFSF14 / LIGHT / CD258 (SAR252067) is a fully human monoclonal antibody targeting LIGHT. It can be used in treatment of treatment of ulcerative colitis and crohn’s disease. MW :141.8 KD.

Anti-TNFSF14 / LIGHT / CD258 (SAR252067) is a fully human monoclonal antibody targeting LIGHT. It can be used in treatment of treatment of ulcerative colitis and crohn’s disease. MW :141.8 KD.

Anti-TNFSF14 / LIGHT / CD258 (SAR252067) is a fully human monoclonal antibody targeting LIGHT. It can be used in treatment of treatment of ulcerative colitis and crohn’s disease. MW :141.8 KD.

Anti-TNFSF2 / TNFa (CDP571) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA). MW :146.9 KD.

Anti-TNFSF2 / TNFa (CDP571) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA). MW :146.9 KD.

Anti-TNFSF2 / TNFa (CDP571) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA). MW :146.9 KD.

Anti-TNFSF2 / TNFa (CMAB008) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA). MW :147.16 KD.

Anti-TNFSF2 / TNFa (CMAB008) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA). MW :147.16 KD.

Anti-TNFSF2 / TNFa (CMAB008) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA). MW :147.16 KD.

Anti-TNFSF2 / TNFa (ESBA 105) is an antibody targeting tumor necrosis factor (TNF).It has an efficient intraocular penetration to anterior and posterior region of eye. MW :145.14 KD.

Anti-TNFSF2 / TNFa (ESBA 105) is an antibody targeting tumor necrosis factor (TNF).It has an efficient intraocular penetration to anterior and posterior region of eye. MW :145.14 KD.

Anti-TNFSF2 / TNFa (ESBA 105) is an antibody targeting tumor necrosis factor (TNF).It has an efficient intraocular penetration to anterior and posterior region of eye. MW :145.14 KD.

Anti-TNFSF2 / TNFa (hMAK195) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA). MW :145.06 KD.

Anti-TNFSF2 / TNFa (hMAK195) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA). MW :145.06 KD.

Anti-TNFSF2 / TNFa (hMAK195) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA). MW :145.06 KD.

Anti-TPSAB1 is a humanized monoclonal antibody against human β-tryptase with the potential to treat mast cell-mediated severe asthma. MW: 150 KD.

Anti-TPSAB1 is a humanized monoclonal antibody against human β-tryptase with the potential to treat mast cell-mediated severe asthma. MW: 150 KD.

Anti-TPSAB1 is a humanized monoclonal antibody against human β-tryptase with the potential to treat mast cell-mediated severe asthma. MW: 150 KD.

Anti-TREM1 / CD354 (PY159) is a humanized agonistic monoclonal antibody targeting triggering receptor expressed on myeloid cells 1 (TREM1), with potential immunomodulating and antineoplastic activities. MW: 143.66 kD.

Anti-TREM1 / CD354 (PY159) is a humanized agonistic monoclonal antibody targeting triggering receptor expressed on myeloid cells 1 (TREM1), with potential immunomodulating and antineoplastic activities. MW: 143.66 kD.

Anti-TREM1 / CD354 (PY159) is a humanized agonistic monoclonal antibody targeting triggering receptor expressed on myeloid cells 1 (TREM1), with potential immunomodulating and antineoplastic activities. MW: 143.66 kD.

Anti-TREM2 (Py314) is a humanized monoclonal antibody that specifically targets the triggering receptor expressed on myeloid cells 2 (TREM2). It can be used in cancer research and in treatment of variety of solid tumor types. MW :145.24 KD.

Anti-TREM2 (Py314) is a humanized monoclonal antibody that specifically targets the triggering receptor expressed on myeloid cells 2 (TREM2). It can be used in cancer research and in treatment of variety of solid tumor types. MW :145.24 KD.

Anti-TREM2 (Py314) is a humanized monoclonal antibody that specifically targets the triggering receptor expressed on myeloid cells 2 (TREM2). It can be used in cancer research and in treatment of variety of solid tumor types. MW :145.24 KD.

Anti-TrkA / NTRK1 is a non-conjugated, rabbit-derived monoclonal antibody targeting TrkA. MW : 145.5 KD.

Anti-TrkA / NTRK1 is a non-conjugated, rabbit-derived monoclonal antibody targeting TrkA. MW : 145.5 KD.

Anti-TrkA / NTRK1 is a non-conjugated, rabbit-derived monoclonal antibody targeting TrkA. MW : 145.5 KD.

Anti-TrkB / NTRK2 is an antibody targeting TrkB. It is used to improve nerve function, including treatment of peripheral neuropathies. MW :146.68 KD.

Anti-TrkB / NTRK2 is an antibody targeting TrkB. It is used to improve nerve function, including treatment of peripheral neuropathies. MW :146.68 KD.

Anti-TrkB / NTRK2 is an antibody targeting TrkB. It is used to improve nerve function, including treatment of peripheral neuropathies. MW :146.68 KD.

Anti-TSHR are unconjugated polyclonal antibodies derived from rabbi. Anti-TSHR are pathophysiologic, and also increases their significance in the diagnosis of autoimmune thyroid diseases and Graves’ disease.

Anti-TSHR are unconjugated polyclonal antibodies derived from rabbi. Anti-TSHR are pathophysiologic, and also increases their significance in the diagnosis of autoimmune thyroid diseases and Graves’ disease.